Alcohol Addiction Medication: Definition, Types, Benefits, Side Effects, Alternatives

​Alcohol addiction medications are treatments designed to assist individuals in managing alcohol addiction. Research by the Federation of American Scientists indicates that these medications are prescribed to 2% of persons with AUD in the U.S.

The mechanism of these medications targets brain chemistry to either reduce the pleasurable effects of alcohol or stabilize neurotransmitter imbalances caused by chronic alcohol use.

Over half (54.8%) of excessive alcohol-related deaths are due to chronic causes such as Alcohol Use Disorder, as published by the New Jersey Department of Human Services, Division of Mental Health and Addiction Services.

The U.S. Food and Drug Administration (FDA) has approved three primary medications for treating AUD, which are disulfiram, naltrexone, and acamprosate. 

The benefits of these medications include a reduction in alcohol cravings, support in maintaining sobriety, and a decrease in the likelihood of heavy drinking episodes. 

Common side effects vary by medication. Disulfiram causes drowsiness, headache, and a metallic taste. Naltrexone leads to nausea, fatigue, and dizziness—acamprosate results in diarrhea, upset stomach, and loss of appetite. ​

Alternatives to medication encompass behavioral therapies, mutual support groups, and lifestyle modifications.

What Is Alcohol Addiction Medication?

Alcohol addiction medications are pharmaceutical medications specifically approved by the U.S. Food and Drug Administration (FDA) to assist individuals in reducing alcohol dependency. A research team led by Dr. Beth Han of NIH’s National Institute on Drug Abuse (NIDA) studied how commonly AUD medications are used. Researchers analyzed data from nearly 43,000 adults participating in the 2019 National Survey on Drug Use and Health (NSDUH). The analysis found that about 5.6% of adults (or 14.1 million people) in the United States in 2019 had AUD in the past year. Among the 14.1 million adults with AUD, only about 223,000 used medications for their disorder.

These pharmacotherapies function by targeting specific neurotransmitter systems in the brain to alleviate cravings, diminish the rewarding effects of alcohol consumption, or induce adverse reactions when alcohol is ingested. Prescription medications, also known as pharmacotherapies, are integral components of Medication-Assisted Treatment (MAT) programs for individuals with Alcohol Use Disorder (AUD). These medications are combined with counseling and behavioral therapies to provide comprehensive support for individuals seeking to overcome Alcohol Use Disorder (AUD).

Emerging treatments, such as the use of GLP-1 receptor agonists like semaglutide (used for weight loss), have shown promise in reducing alcohol cravings. 

How Does Alcohol Addiction Medication Work?

Alcohol addiction medications work through distinct mechanisms to assist individuals in managing Alcohol Use Disorder (AUD). Naltrexone operates as a competitive antagonist at mu-opioid receptors, potentially reducing alcohol cravings and consumption by blocking the euphoric effects associated with alcohol intake. In a study “Effectiveness of Acamprosate in the Treatment of Alcohol Dependence” by WILLIAM E. CAYLEY, et al., 2011, oral naltrexone (50 mg per day) is associated with a reduced risk of return to heavy drinking, with a number needed to treat (NNT) of 12.

According to the Substance Abuse and Mental Health Administration (SAMHSA), acamprosate’s exact mechanism remains not fully understood; however, it is believed to modulate the glutamatergic neurotransmitter system, thereby restoring the balance between excitatory and inhibitory neurotransmission disrupted by chronic alcohol exposure. According to the same study, acamprosate is associated with a reduced risk of any drinking, with an NNT of 9. ​

Disulfiram functions differently by inhibiting the enzyme acetaldehyde dehydrogenase, leading to an accumulation of acetaldehyde when alcohol is consumed. This accumulation results in unpleasant physical reactions, such as nausea and flushing, thereby deterring individuals from drinking. ​

Who Needs Alcohol Addiction Medication?

Individuals who engage in heavy drinking, have unsuccessful rehab experiences, or are prone to relapse need medication for alcohol addiction. Medication-assisted treatment (MAT) is particularly beneficial for these groups. 

Those who need medications are:

• Heavy Drinkers: Those who consume alcohol excessively and struggle to reduce intake find medications like naltrexone beneficial. Research “Effectiveness of Acamprosate in the Treatment of Alcohol Dependence” by WILLIAM E. CAYLEY, et al. 2011, indicates that oral naltrexone (50 mg/day) is associated with a reduced risk of returning to heavy drinking, with a number needed to treat (NNT) of 12. ​
• Individuals with Previous Unsuccessful Rehabilitation Attempts: For those who have not achieved sustained sobriety through prior rehab efforts, incorporating medications such as acamprosate enhances outcomes. A study, “Sobering Perspectives on the Treatment of Alcohol Use Disorder,” by Wid Yaseen et al., has shown that acamprosate is associated with a reduced risk of any drinking, with an NNT of 9.
• Individuals Prone to Relapse: Those with a history of relapse benefit from medications like disulfiram, which deters drinking by causing unpleasant physical reactions when alcohol is consumed.

Despite the potential benefits, the utilization of MAT for AUD remains low. According to a study, “Sobering Perspectives on the Treatment of Alcohol Use Disorder” by Wid Yaseen et al., in 2021, only 2% of Americans with AUD received pharmacotherapy.

What Are the FDA-Approved Medications for Alcohol Addiction?

The FDA-approved medications for alcohol addiction are Naltrexone, Acamprosate, Disulfiram, and Nalmefene. These medications assist individuals in managing Alcohol Use Disorder (AUD) by targeting different pathways to reduce cravings and discourage alcohol consumption.​

FDA-Approved Medications for alcohol addiction are:

Naltrexone

Naltrexone, marketed under brand names such as Revia® and Vivitrol®, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alcohol Use Disorder (AUD). It is available in two forms: an oral tablet taken once daily and an extended-release intramuscular injection administered once monthly. Naltrexone functions as an opioid receptor antagonist, blocking the euphoric effects associated with alcohol consumption, thereby reducing cravings and the likelihood of relapse.​

Research has demonstrated its efficacy in treating alcohol dependence. For instance, a study “Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence” by James C. Garbutt, et al., 2005, published in the Journal of the American Medical Association, found that long-acting naltrexone was well tolerated and resulted in reductions in heavy drinking among treatment-seeking alcohol-dependent patients during 6 months of therapy. Additionally, research “Three genes predict the success of naltrexone in alcohol dependence treatment” by Kristin Marquardt, 2020, published by the Medical University of South Carolina, indicates that genetic factors influence individual responses to naltrexone, suggesting that personalized approaches enhance treatment outcomes. These findings underscore naltrexone’s role as an effective component in the management of AUD.

Acamprosate

Acamprosate, marketed under the brand name Campral®, is a medication approved by the U.S. Food and Drug Administration (FDA) for maintaining abstinence in individuals with Alcohol Use Disorder (AUD). It is administered orally at a dosage of 666 mg (two 333 mg tablets) three times daily. The exact mechanism of action is not fully understood; however, acamprosate is believed to interact with glutamate and GABA neurotransmitter systems, helping to restore the balance between neuronal excitation and inhibition disrupted by chronic alcohol exposure. 

Research has demonstrated its effectiveness in supporting continuous abstinence after detoxification. A meta-analysis of 24 randomized controlled trials, “The clinical pharmacology of acamprosate” by Nicola J Kalk, et al., 2014, found that patients treated with acamprosate had a 14% lower risk of returning to any drinking compared to those receiving a placebo, with a number needed to treat (NNT) of 9. Additionally, acamprosate-treated patients maintained cumulative abstinence for 11% longer than those on placebo, as reported by a meta-analysis, “Effectiveness of Acamprosate in the Treatment of Alcohol Dependence” by WILLIAM E. CAYLEY, 2011. 

Another study, “Acamprosate (Campral) for Treatment of Alcoholism” by KAM HUNTER, et al., reported that individuals taking Acamprosate had a 36% higher likelihood of remaining abstinent over six months compared to those not taking the medication. However, despite its efficacy, according to the U.S. Food and Drug Administration, Acamprosate is underutilized, and less than 4% of people with AUD receive medication-assisted treatment. These findings underscore acamprosate’s role as an effective and safe treatment strategy for supporting continuous abstinence in alcohol-dependent patients.

Disulfiram

Disulfiram, marketed under the brand name Antabuse®, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic alcohol dependence. It is administered orally in tablet form, with a common dosage of 250 mg once daily. Disulfiram functions as an alcohol-aversive agent by inhibiting the enzyme aldehyde dehydrogenase, leading to an accumulation of acetaldehyde when alcohol is consumed. This accumulation results in unpleasant physical reactions, such as nausea, flushing, and palpitations, thereby deterring individuals from drinking.​

The effectiveness of disulfiram in treating alcohol dependence has been a subject of debate. A meta-analysis of 22 randomized controlled trials, “Disulfiram Efficacy in the Treatment of Alcohol Dependence,” by Marilyn D Skinner, et al., 2014, found a higher success rate for disulfiram compared to controls, with a Hedges’ g effect size of 0.58 (95% CI = 0.35–0.82). However, this significant effect was observed primarily in open-label trials (g = 0.70, 95% CI = 0.46–0.93), while blinded studies did not demonstrate a significant benefit (g = 0.01, 95% CI = −0.29–0.32). These findings suggest that disulfiram’s efficacy is enhanced in supervised settings or among highly motivated patients with strong social support systems. Incorporating disulfiram into an alcohol recovery treatment program has been associated with an abstinence rate of more than 50%, as reported by “Sobering Perspectives on the Treatment of Alcohol Use Disorder” by Wid Yaseen et al. However, the long-term efficacy of disulfiram remains uncertain, and more homogeneous, high-quality studies are needed to fully assess its effectiveness.

Nalmefene

Nalmefene, marketed under the brand name Selincro®, is an opioid receptor antagonist approved in the European Union for reducing alcohol consumption in adult patients with alcohol dependence. It is administered orally on an as-needed basis, allowing individuals to take the medication when they anticipate a high risk of drinking. Nalmefene works by modulating the brain’s reward system, reducing the reinforcing effects of alcohol and thereby diminishing the urge to drink. As of now, nalmefene is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of alcohol dependence.​

Research has demonstrated nalmefene’s efficacy in reducing alcohol consumption. For instance, a randomized controlled trial “Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis” by Nozomu Hashimoto, et al., 2022, found that patients treated with nalmefene experienced a significant reduction in heavy drinking days (HDD) compared to placebo, with a mean difference of 4 days per month at week 12. Additionally, total alcohol consumption (TAC) decreased significantly in the nalmefene group compared to the placebo. These findings suggest that while nalmefene is effective in reducing alcohol consumption for some patients, its overall value in treating alcohol addiction is not yet fully established.

What Are the Off-Label Medications for Alcohol Addiction?

The off-label medications for alcohol addiction are Topiramate, Baclofen, and Gabapentin. Off-label medications, not approved by the U.S. Food and Drug Administration (FDA) for treating Alcohol Use Disorder (AUD), have been explored for their potential benefits. 

These include:​

• Topiramate: An anticonvulsant that modulates neurotransmitters to reduce cravings and promote abstinence. Its off-label status stems from limited large-scale studies confirming its efficacy.​ A systematic review and meta-analysis, “Pharmacotherapy for Alcohol Use Disorder” by Melissa McPheeters, et al., 2023, reported that topiramate was associated with a significant reduction of 62.4% of heavy drinking days compared to placebo.
• Baclofen: A muscle relaxant that activates GABA receptors, potentially decreasing alcohol cravings. Its off-label use is due to inconsistent research outcomes.​ The same systematic review and meta-analysis reported that baclofen was associated with a 28.6% reduction in the percentage of heavy drinking days compared to placebo.
• Gabapentin: Originally an anticonvulsant, it alleviates withdrawal symptoms and reduces heavy drinking by stabilizing neural activity. Its off-label designation arises from insufficient robust clinical trials.​ It helps reduce alcohol consumption and support abstinence, though more research is needed to confirm these findings.

Their off-label status persists due to the need for more comprehensive research to establish consistent efficacy and safety profiles.

What Are the Benefits of Alcohol Addiction Medication?

​The benefits of alcohol addiction medications include maintaining sobriety, improving mental health, reducing relapse risk, and enhancing overall quality of life.​ 

The benefits of alcohol addiction medications are as follows:

• Maintaining Sobriety: Medications like acamprosate (Campral®) help individuals sustain abstinence by restoring the balance of neurotransmitters disrupted by chronic alcohol use, as reported by the Office of Addiction Services and Supports (OASS). ​
• Improving Mental Health: By reducing alcohol consumption, these medications alleviate symptoms of depression and anxiety, leading to enhanced overall well-being.​
• Reducing Relapse Risk: Naltrexone (Revia®, Vivitrol®) decreases the pleasurable effects of alcohol, thereby lowering the likelihood of relapse. A study, “Pharmacotherapy for Alcohol Dependence: Anticraving Medications for Relapse Prevention,” by Young-Chul Jung, et al. 2006, has shown that patients treated with naltrexone had significantly lower rates of relapse to heavy drinking compared to those receiving a placebo.
• Enhancing Quality of Life: By supporting recovery, these medications enable individuals to rebuild relationships, improve occupational performance, and engage more fully in daily activities.​

Incorporating these medications into a structured treatment plan, alongside counseling and support, significantly improves outcomes for individuals with Alcohol Use Disorder.

Can Alcohol Addiction Medication Reduce Cravings?

Yes,  alcohol addiction medications can reduce alcohol cravings in individuals. Naltrexone, an opioid receptor antagonist, diminishes the rewarding effects of alcohol consumption, thereby reducing the desire to drink. Research “Naltrexone and the Treatment of Alcohol Dependence” by Joseph R Volpicelli, et al., has demonstrated that naltrexone lowers relapse rates to heavy drinking compared to placebo. Acamprosate works by stabilizing brain chemistry disrupted by chronic alcohol use, which helps decrease cravings and supports abstinence. Research by the Office of Addiction Services and Supports (OASS) indicates that acamprosate is more effective when initiated after cessation of drinking. Additionally, semaglutide, a GLP-1 receptor agonist primarily used for type 2 diabetes and weight management, also reduces alcohol cravings and consumption. Participants receiving semaglutide reported a significant decrease in alcohol intake compared to those on placebo. These findings highlight the potential of these medications in managing alcohol cravings and supporting recovery efforts.​

What Are the Side Effects of Alcohol Addiction Medication?

The side effects of alcohol addiction medication include weakness, decreased appetite, vomiting, diarrhea, gas, nausea, anxiety, garlic-like taste, depression, dizziness, dry mouth, sweating, trouble sleeping, itching, sweating, and numbness or tingling. The side effects of alcohol addiction medications vary depending on the specific drug used. ​Alcohol addiction medications, including acamprosate, disulfiram, and naltrexone, are prescribed to support individuals in their recovery from alcohol use disorder. While these medications are effective, they also cause side effects that vary depending on the specific drug.

Below is an overview of potential side effects associated with each FDA-approved medication:​

• Naltrexone: Common side effects include nausea, headache, dizziness, fatigue, and insomnia. In clinical trials, gastrointestinal symptoms such as decreased appetite, nausea, vomiting, diarrhea, and abdominal pain were reported in the study “Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence” by Stephanie L Yahn, et al., 2013.
• Acamprosate: Patients experience diarrhea, anxiety, depression, and insomnia. A study, “Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings,” published by the Agency for Healthcare Research and Quality in 2014, noted that acamprosate-treated patients had a higher risk of anxiety, diarrhea, and vomiting compared to those receiving a placebo.
• Disulfiram: Side effects include drowsiness, headache, and a metallic or garlic-like taste in the mouth. According to a study, “Addiction Addiction Free Access Does disulfiram have a role in alcoholism treatment today?” by RICHARD K. FULLER, et al. 2003, disulfiram does not appear to increase the incidence of side effects compared to placebo, except for drowsiness.

What Are the Alternative Treatments to Alcohol Addiction Medication?

The alternative treatments to alcohol addiction medication are Behavioral Therapies, Support groups, Holistic Approaches, and Nutritional Support. They are diverse and aim to address the multifaceted nature of addiction. Behavioral therapies, such as cognitive-behavioral therapy (CBT), focus on identifying and modifying the thought patterns and behaviors that contribute to alcohol use, equipping individuals with coping strategies to manage triggers and prevent relapse. Support groups, including Alcoholics Anonymous (AA) and SMART Recovery, offer peer support and a sense of community, which is instrumental in maintaining sobriety. Holistic approaches, encompassing practices like acupuncture, meditation, and yoga, strive to heal the mind, body, and spirit, promoting overall well-being and stress reduction. Nutritional support emphasizes a balanced diet to repair the physical damage caused by alcohol use and to support mental health, recognizing the role of proper nutrition in recovery. These alternative treatments are utilized individually or in combination, depending on the individual’s unique needs and preferences, to effectively support alcohol addiction treatment.

​

The alternative treatments to alcohol addiction medication are as follows:

• Behavioral therapies: Behavioral therapies help people change thoughts, emotions, and behaviors linked to alcohol use. Approaches like CBT, MET, contingency management, and community reinforcement build coping skills, strengthen motivation, and address co‑occurring issues such as PTSD to support long-term recovery.
• Support groups: Support groups provide a peer-based setting to share experiences, gain encouragement, and stay accountable. Programs like AA, SMART Recovery, and LifeRing use regular meetings, peer mentoring, milestones, and group discussion to reduce isolation and help maintain sobriety.
• Holistic approaches: Holistic treatments focus on the whole person—mind, body, and spirit. They may include mindfulness, meditation, yoga, tai chi, nutrition counseling, acupuncture, and massage to manage stress, cravings, and emotional triggers while supporting a balanced, recovery-focused lifestyle.
• Nutritional support: Nutritional support aims to restore health by correcting deficiencies common in alcohol use disorder. It emphasizes balanced meals, key vitamins and minerals (such as B vitamins and zinc), and adequate hydration to improve energy, physical healing, and overall well-being during recovery.

Is Medication Alone Enough to Cure Alcohol Addiction?

No, medication alone is not sufficient to cure alcohol addiction. Research “Alcohol use disorder: Psychosocial management by Andrew J Saxon, et al. indicates that combining pharmacotherapy with behavioral therapies yields more effective outcomes for individuals with alcohol use disorder (AUD). A systematic review, “Pharmacotherapy for Alcohol Use Disorder,” by Melissa McPheeters, et al. 2023 highlighted that integrating cognitive-behavioral therapy (CBT) with medications like naltrexone or acamprosate enhances treatment efficacy compared to medication alone. Similarly, the Substance Abuse and Mental Health Services Administration (SAMHSA) emphasizes that a combination of medication and therapy successfully treats substance use disorders, with medications helping to sustain recovery. Therefore, a comprehensive treatment plan that includes both medication and behavioral interventions is recommended for effective management of alcohol addiction.

Do You Need a Prescription For Alcohol Addiction Medications?

Yes, a prescription is required for medications used to treat alcohol use disorder (AUD). The U.S. Food and Drug Administration (FDA) has approved several medications for AUD, including disulfiram, naltrexone, and acamprosate, all of which are available only by prescription. These medications are most effective when used in conjunction with counseling and support groups. Despite their availability and effectiveness, these medications are underutilized. A study by the National Institutes of Health in 2021 found that only 1.6% of individuals with AUD had been prescribed these medications. Therefore, consulting a healthcare provider is necessary to determine the most appropriate medication and to obtain a prescription as part of a comprehensive treatment plan for alcohol addiction.

Is Alcohol Addiction Medication Safe for Long-Term Use?

Yes, alcohol addiction medications are considered safe for long-term use when administered under medical supervision. A comprehensive meta-analysis, “Pharmacotherapy for Alcohol Use Disorder” by Melissa McPheeters, et al., 2023, published in JAMA Network Open, reviewed 118 clinical trials encompassing 20,976 participants and found that both 50 mg/day of oral naltrexone and acamprosate significantly improved alcohol consumption-related outcomes compared to placebo, supporting their use as first-line therapies for AUD. Additionally, the Substance Abuse and Mental Health Services Administration (SAMHSA) notes that naltrexone and acamprosate medications are most effective when combined with counseling and behavioral therapies, underscoring the importance of a comprehensive treatment approach. Therefore, with appropriate medical oversight, these medications are a safe and effective component of long-term AUD management.​ 

Are Alcohol Addiction Medications Safe for Pregnant Women?

No, alcohol addiction medications are not safe for pregnant women, and their use is approached with caution. According to a scoping review, “The Safety of Alcohol Pharmacotherapies in Pregnancy” by Ebony Quintrell, alcohol pharmacotherapies pose unknown teratogenic risks in pregnancy and are therefore recommended to be avoided. Similarly, the World Federation of Societies of Biological Psychiatry and the International Association for Women’s Mental Health recommend abstinence from alcohol during pregnancy and advise that the use of pharmacological treatments for alcohol use disorders be evaluated on a case-by-case basis, considering the potential risks and benefits. Given the potential risks associated with both alcohol consumption and pharmacotherapy during pregnancy, pregnant women need to consult healthcare professionals to determine the safest and most effective treatment options.​

Can You Get Addicted to Alcohol Addiction Medications?

No, you cannot get addicted to alcohol addiction medications. Medications approved for treating alcohol use disorder (AUD), such as acamprosate, disulfiram, and naltrexone, do not possess addictive properties. These medications function through various mechanisms to support recovery from alcohol dependence. For instance, naltrexone is an opioid receptor antagonist that diminishes the rewarding effects of alcohol, thereby reducing cravings. Acamprosate is believed to restore the balance of neurotransmitters disrupted by chronic alcohol consumption, aiding in the maintenance of abstinence. Disulfiram works by inhibiting the enzyme acetaldehyde dehydrogenase, leading to unpleasant reactions when alcohol is consumed, which discourages drinking. Importantly, these medications do not produce euphoric effects or reinforcement behaviors associated with alcohol addiction. Therefore, under the guidance of a healthcare professional, these medications are safely incorporated into a comprehensive treatment plan for AUD without the risk of developing a new addiction.